



Les Pensières Center for Global Health, Veyrier-du-Lac, France, May 6-17, 2024

PROGRAM (AS OF 26 April 2024)

Organized by

The University of Geneva and
the Mériem Foundation



**UNIVERSITÉ
DE GENÈVE**



With the co-sponsorship of

- Africa Centres for Disease Control and Prevention
- Bill & Melinda Gates Foundation
- Centers for Disease Control and Prevention (CDC)
- Coalition for Epidemic Preparedness Innovations (CEPI)
- European Centre for Disease Prevention and Control (ECDC)
- European & Developing Countries Clinical Trials Partnership (EDCTP)
- European Society for Paediatric Infectious Diseases (ESPID)
- Johns Hopkins Bloomberg School of Public Health
- International Pediatric Association
- National Foundation for Infectious Diseases (NFID)
- National Institutes of Health (NIH/NIAID-USA)
- World Health Organization



MONDAY 6 MAY 2024		
09:00	Opening and objectives of the course	Alain Mérieux , President, Fondation Mérieux Kamel Senouci , Director, ADVAC, University of Geneva
09:30	Administrative and logistic briefing	Bénédicte Pansier , Director, Les Pensières Center for Global Health, Fondation Mérieux
SESSION 1 – THE VACCINES JOURNEY: FROM VACCINES TO VACCINATION & THE IMPACT OF VACCINES		Chair: Adam Finn , University of Bristol, UK
09:40-10:05	From research to individual protection: the A-to-Z vaccine's journey	Arnaud Didierlaurent , University of Geneva
10:05-10:25	Discussion	
10:25-10:50	A quick overview of the vaccinology concepts	Kamel Senouci , University of Geneva
10:50-11:10	Discussion	
11:10-11:40	Break	
11:40-12:05	Measuring vaccination's impact in populations	Roy Anderson , London Centre for Neglected Tropical Disease Research, Imperial College, UK
12:05-12:25	Discussion	
12:25-12:40	Time for students to reflect personally on the learnings	
12:40-14:00	Lunch	
14:00-14:25	Where are we with vaccine-preventable diseases & immunization coverage worldwide: the state of the immunization	Kate O'Brien , WHO, Geneva
14:25-14:45	Discussion	
14:45-15:10	The determinants of a good immunization coverage and how GAVI is supporting countries to reach more children	Aurelia Nguyen , Gavi, The Vaccine Alliance, Geneva
15:10-15:30	Discussion	
15:30-15:55	Using vaccines to solve a public health problem: the example of Polio eradication	Ananda Bandyopadhyay , Bill & Melinda Gates Foundation, USA
15:55-16:15	Discussion	
16:15-16:30	Time for students to reflect personally on the learnings	
16:30-18:30	Self-presentation of individual participants (background, interests in life...)	
18:30-19:00	welcome reception	
19:00	Dinner	

TUESDAY 7 MAY 2024

SESSION 2 – HOW VACCINES WORK		Chair: Arnaud Didierlaurent, University of Geneva
09:00-09:25	How are vaccine responses elicited? What a vaccinologist should know about the basic aspects of immunological responses (a) B-cell responses	Claire-Anne Siegrist, University of Geneva
09:25-09:45	Discussion	
09:45-10:15	Break	
10:15-10:40	How are vaccine responses elicited? What a vaccinologist should know about the basic aspects of immunological responses (b) T-cell responses	Claire-Anne Siegrist, University of Geneva
10:40-11:00	Discussion	
11:00-11:25	Use and limitations of correlates of immunity in vaccinology	Andrew Pollard, University of Oxford, UK
11:25-11:45	Discussion	
11:45-11:55	Time for students to reflect personally on the learnings	
11:55-13:25	Lunch	
13:25-13:50	Vaccines and mucosal immunity	Adam Finn, University of Bristol, UK
13:50-14:10	Discussion	
14:10-14:55	Vaccines and immunological memory Quiz - Q&A	Claire-Anne Siegrist, University of Geneva
14:55-15:20	Immunological memory	Rafi Ahmed, Emory University, USA
15:20-15:40	Discussion	
15:40-16:10	Break	
16:10-16:35	Tailoring vaccine immunogenicity with adjuvants	Arnaud Didierlaurent, University of Geneva
16:35-16:55	Discussion	
SESSION 3 – VACCINE TECHNOLOGY, MANUFACTURING AND APPROVAL (Part 1/3)		Chair: Emily Erbelding, Director, DMID, NIH, USA
16:55-17:20	The complexity of quality control in vaccine manufacturing	Philippe Juvin, Sanofi Pasteur, Lyon, France
17:20-17:40	Discussion	
17:40-18:00	Time for students to reflect personally on the learnings	
18:00-19:00	Mentoring	
19:00	Dinner	

WEDNESDAY 8 MAY 2024

SESSION 3 – VACCINE TECHNOLOGY, MANUFACTURING AND APPROVAL (Part 2/3)		Chair: Emily Erbeling, Director, DMID, NIH, USA
09:00-09:25	Landscape in vaccine and immunization technologies	Cristina Casetti, NIH-NIAID, USA
09:25-09:45	Discussion	
09:45-10:10	Concepts of Chemistry, Manufacturing, and Controls (CMC) for vaccines	Ozzie Berger, Hillevax, USA
10:10-10:30	Discussion	
10:30-11:00	Break	
11:00-11:25	The role of Regulatory Agencies	Marco Cavaleri EMA
11:25-11:45	Discussion	
11:45-12:30	Time for students to reflect personally on the learnings	
12:30-13:45	Lunch	
13:45-16:00	Small Group Exercise 1 How to manage regulatory requirements during vaccine development and vaccine production in both HICs and LMICs Participants to share own country's experience and case study-role playing (4 groups)	Facilitators Ozzie Berger, Hillevax, USA, Arnaud Didierlaurent, University of Geneva, Norman Baylor, Biologics Consulting Inc., USA; Pieter Neels, Vaccine-advice, Belgium, David Kaslow, US Food and Drug Administration, Marco Cavaleri EMA, Veronica Gambillara, Pureos Bioventures, Switzerland, Luis Jodar, Pfizer Inc., USA
16:00-16:30	Break	
16:30-18:00	Interactive Session 1: Special lecture from Industry	
Special lecture: THE 8th LAMBERT LECTURE		
18:05-18:10	Introduction	Paul-Henri Lambert
18:10-18:50	RSV vaccines from research to implementation	Barney Graham
18:50-19:00	Discussion	
19:00	Dinner	

THURSDAY 9 MAY 2024

SESSION 3 – VACCINE TECHNOLOGY, MANUFACTURING AND APPROVAL (Part 3/3)		Chair: Emily Erbelding , Director, DMID, NIH, USA
09:00-09:25	Delivering a pandemic vaccine in 100 Days: what does it take?	Jakob Cramer , CEPI, UK
09:25-09:45	Discussion	
09:45-10:45	Interactive session 2 Everything you always wanted to know on what makes funders support research-development: ask all your questions to governmental agency, venture capitalists, industry and philanthropic organizations. Q&A	Panelists: Emily Erbelding , DMID, NIH, USA, Veronica Gambillara , Pureos Bioventures, Switzerland, Luis Jodar , Pfizer Inc., USA; Jakob Cramer , CEPI, UK
10:45-11:00	Break	
SESSION 4 – ASSESSING VACCINES IN CLINICAL TRIALS (Part 1/2)		Chair: Hanna Nohynek , Finnish Institute for Health and Welfare, Finland
11:00-11:25	Clinical trials: an overview of issues to be considered	Myron Levine , University of Maryland, USA
11:25-11:45	Discussion	
11:45-12:10	Introduction to statistical aspects of clinical trials, part 1: defining sample size	Peter Smith , London School of Hygiene and Tropical Medicine, UK
12:10-12:30	Discussion	
12:45-15:00 12:30-13:10 <i>working lunch</i>	Small group exercise 2 How to design, recruit volunteers for, and analyze the results of selected phase II trials: Group 1 <i>S. aureus</i> Group 2 Ebola Group 3 Dengue Group 4 RSV Group 5 Monkeypox Group 6 Typhoid conjugate vaccines Group 7 Coronavirus	Facilitators: Veronica Gambillara Pieter Neels Norman Baylor & Anna Durbin Romina Libster Kari Johansen Kamel Senouci Emily Erbelding
15:00-15:25	Assessing herd protection and vaccine effectiveness (and use for licensure)	John Clemens , International Vaccine Institute (IVI), Republic of Korea
15:25-15:45	Discussion	
15:45-16:10	Clinical trials: role of a Data Safety Monitoring Board (DSMB)	Robert Heyderman , University College London, UK
16:10-16:30	Discussion	
16:30-16:50	Break	
16:50-17:15	Human Challenge Trials	Chris Chiu , Imperial College London, UK
17:15-17:25	Discussion	
17:25-17:45	Time for students to reflect personally on the learnings	
Special lecture: THE 16TH PLOTKIN LECTURE		

17:45-17:50	Introduction	Edwin Asturias , Children's Hospital Colorado, USA
17:50-18:30	Climate Change and Immunization	Kate O'Brien , WHO Geneva (TBC)
18:30-18:55	Discussion	
19:00	Dinner	

FRIDAY 10 MAY 2024

SESSION 5 – VACCINE SAFETY - ASSESSMENT OF ADVERSE EFFECTS		Chair: Kari Johansen, Public Health Agency, Sweden
09:00-09:25	How do vaccines cause adverse events?	Kawsar Talaat, Johns Hopkins Bloomberg, School of Public Health, Baltimore, USA
09:25-09:45	Discussion	
09:45-10:10	Vaccination and immune-mediated diseases	Christiane Eberhardt, University of Geneva
10:10-10:30	Discussion	
10:30-11:00	Break	
11:00-11:25	WHO Guidance on how to detect and manage safety issues	Madhav Balakrishnan, WHO, Geneva
11:25-11:45	Discussion	
11:45-12:10	Population-based post-licensure surveillance	Nick Andrews, UKHSA, UK
12:10-12:30	Discussion	
12:30-14:00	Lunch	
14:00-14:25	Immunization safety in low- and middle-income country vaccination programs	Kamel Senouci, University of Geneva
14:25-14:45	Discussion	
SESSION 4 – ASSESSING VACCINES IN CLINICAL TRIALS (Part 2/2)		Chair: Hanna Nohynek, Finnish Institute for Health and Welfare, Finland
14:45-15:10	Introduction to statistical aspects of clinical trials, part 2: statistical assessment and reporting of phase 3 trials	Peter Smith, LSHTM, UK
15:10-15:30	Discussion	
15:30-15:45	Break	
15:45-17:45	Small group exercise 3 Designing and analyzing the results of selected phase 3 trials Seven Groups	Facilitators: Nick Andrews, Brad Gessner, Kari Johansen, Romina Libster, Pieter Neels, Hanna Nohynek, Peter Smith
17:45-18:45	Time for students to reflect personally on the learnings & Mentoring	
19:00	Dinner	

SATURDAY 11 MAY 2024		
SESSION 6 - ETHICAL ISSUES		Chair: Kari Johansen , Public Health Agency, Sweden
09:00-09:25	Applied ethics in immunization programs and practice	Keymanthri Moodley , Stellenbosch University, South Africa
09:25-09:45	Discussion	
09:45-10:10	Principles, guidelines and frameworks for ethical considerations in clinical trials of vaccines	Catherine Slack , University of KwaZulu-Natal, South Africa
10:10-10:30	Discussion	
10:30-10:50	Break	
10:50-13:00	Small group exercise 4 Ethical considerations in vaccine trials Seven Groups	Facilitators: Edwin Asturias, Betty Dodet, Kamel Senouci, Kari Johansen, Pieter Neels, Catherine Slack, Romina Libster
13:00-13:10	Time for students to reflect personally on the learnings of the morning	
13:10-13:40	Lunch	

MONDAY 13 MAY 2024		
08:50-09:00	Ethical considerations in vaccine trials: Recap	Catherine Slack , University of KwaZulu-Natal, South Africa
SESSION 2 – HOW VACCINES WORK (cont.)		
09:00-09:25	Non-specific effects of vaccines	Nigel Curtis , The Royal Children's Hospital, Melbourne, Australia
09:25-09:45	Discussion	
SESSION 7 – DECISION MAKING FOR VACCINES (Part 1/2)		Chair: Kamel Senouci , University of Geneva
09:45-10:10	The decision-making processes for vaccines use: global, regional and local perspectives	Rudzani Muloiwa , University of Cape Town, South Africa
10:10-10:30	Discussion	
10:30-11:00	Break	
11:00-11:25	The example of the WHO SAGE decision making processes	Joachim Hombach , WHO Geneva
11:25-11:45	Discussion	
11:45-12:10	The role of health economics (including modelling) as a tool in analyzing vaccine policy options	Marc Brisson , Laval University
12:10-12:30	Discussion	
12:30-13:30	Lunch	
13:30-15:30	Small group exercise 5, Part 1 Decision-making for the evaluation and impact assessment of new vaccines introduced in selected countries: safety and effectiveness Part 1: Preparation and data analysis Group 1 Rotavirus Group 2 HPV Group 3 Dengue Group 4 Coronavirus H1C Group 5 Malaria Group 6 RSV Adults Group 7 RSV	Facilitators: Umesh Parashar Kamel Senouci & Sabrina Bacci Brad Gessner & Hanna Nohynek Kari Johansen Kathy Neuzil Keipp Talbot Janet Englund & Naveen Thacker
15:30-16:00	Break	
SESSION 8 – UPDATES ON VACCINES (part 1/3)		Chair: Anna Durbin , Johns Hopkins B. School of Public Health, USA
16:00-16:25	Response to polysaccharide and conjugate vaccines	David Goldblatt , University College London, UK
16:25-16:45	Discussion	
16:45-17:25	Pneumococcal conjugate vaccines: Efficacy and limitations of available vaccines and existing and potential vaccination strategies	Ron Dagan , Soroka Medical Center, Beer Sheva, Israel Keith Klugman , Bill & Melinda Gates Foundation, USA
17:25-17:45	Discussion	
17:45-18:30	Mentoring	
18:30-18:45	Time for students to reflect personally on the learnings & Mentoring	
19:00	Dinner	

TUESDAY 14 MAY 2024

SESSION 8 – UPDATES ON VACCINES (part 2/3)		Chair: Anna Durbin , Johns Hopkins B. School of Public Health, Baltimore, USA
08:30-08:55	HPV vaccines	Margaret Stanley , Cambridge University, UK (VIA ZOOM)
08:55-09:15	Discussion	
09:15-09:40	Typhoid vaccines	Kathy Neuzil , Center for Vaccine Development, University of Maryland, Baltimore, USA
09:40-10:00	Discussion	
10:00-10:25	Break	
10:25-10:50	Meningococcal vaccines	Shamez Ladhani , UKHSA, UK
10:50-11:10	Discussion	
11:10-11:35	Vaccines against arboviruses (Dengue, Zika, Chikungunya)	Anna Durbin , Johns Hopkins Bloomberg School of Public Health, USA
11:35-11:55	Discussion	
11:55-12:05	Time for students to reflect personally on the learnings	
12:05-13:35	Lunch	
13:35-14:00	Rotavirus and norovirus vaccines	Umesh Parashar , Centers for Disease Control, Atlanta, USA
14:00-14:20	Discussion	
14:20-14:45	Flu vaccines	Kathy Neuzil , University of Maryland, Baltimore, USA
14:45-15:05	Discussion	
15:05-15:30	COVID vaccines	Hanna Nohynek , Finnish Institute for Health and Welfare, Finland
15:30-15:50	Discussion	
15:50-16:20	Break	
SESSION 7 – DECISION MAKING FOR VACCINES (Part 2/2)		
16:20-17:30	Small group exercise 5, Part 2 Decision-making for the evaluation and impact assessment of new vaccines introduced in selected countries: safety and effectiveness Part 2: Presentations, discussion and conclusions Group 1 Rotavirus Group 2 HPV Group 3 Dengue Group 4 Coronavirus H1C Group 5 Malaria Group 6 RSV Adults Group 7 RSV	Facilitators: Umesh Parashar Kamel Senouci & Sabrina Bacci Brad Gessner & Hanna Nohynek Kari Johansen Kathy Neuzil Keipp Talbot Janet Englund & Naveen Thacker
17:30-17:45	Time for students to reflect personally on the learnings	
17:45-18:30	Alumni session	Jennifer Moisi & Rudzani Muloiwa
18:30	Cocktail-Diner	

WEDNESDAY 15 MAY 2024		
SESSION 9 - SELECTING APPROPRIATE VACCINATION STRATEGIES		Chair: Janet Englund , Children's Hospital and Regional Medical Center, Seattle, USA
09:00-09:25	Vaccination and pregnancy	Janet Englund , Children's Hospital and Regional Medical Center, Seattle, USA
09:25-09:45	Discussion	
09:45-10:10	Vaccination in early life	Christiane Eberhardt , University of Geneva
10:10-10:30	Discussion	
10:30-11:00	Break	
11:00-11:25	Vaccination schedules: Past, present and future - is there some rationale?	Edwin Asturias , Children's Hospital Colorado, USA
11:25-11:45	Discussion	
11:45-12:10	Vaccine responses and efficacy in the elderly	Keipp Talbot , Vanderbilt University, USA
12:10-12:30	Discussion	
12:30-12:55	Vaccination in immuno-compromised individuals, including HIV positive patients	Janet Englund , Children's Hospital and Regional Medical Center, Seattle, USA
12:55-13:20	Discussion	
13:20-14:30	Lunch	
14:45-17:00	Parallel sessions	
	1.National decision-making for immunization programmes	Christoph Steffen WHO Geneva & Melinda Wharton , US-CDC
	2.Clinical vaccinology: patients' problem solving	Alessandro Diana , and Christiane Eberhardt , University of Geneva
	3.New approaches towards vaccination e-registries	Julia Stowe , UKHSA, UK, Carolina Danovaro , WHO Geneva, and Kari Johansen , Public Health Institute, Sweden
	4. Cold Chain management	Souleymane Kone , WHO Geneva
	5. AEFI: Causality assessment	Madhav Balakrishnan , WHO, Geneva
	6. Data for immunization program management	Jan Grevendonk & Laure Dumolard , WHO Geneva
17:00-17:30	Time for students to reflect personally on the learnings	
17:30-19:00	Social time (Soccer game, Pétanque, Mølky...)	
19:00-19:30	Light refreshment	
19:30	Dinner	

THURSDAY 16 MAY 2024		
SESSION 8 – UPDATES ON VACCINES (Part 3/3)		Chair: Edwin Asturias, Children’s Hospital Colorado, USA
09:15-09:40	Malaria vaccines	Mary Hamel, WHO, Geneva
09:40-10:00	Discussion	
10:00-10:30	Break	
10:30-10:55	Cholera vaccines	Alejandro Cravioto, National Autonomous University of Mexico
10:55-11:15	Discussion	
11:15-11:40	Tuberculosis vaccines	Helen McShane, University of Oxford, UK
11:40-12:00	Discussion	
12:00-12:10	Time for students to reflect personally on the learnings of the morning	
12:10-13:45	Lunch	
SESSION 10 – REACHING SPECIFIC GROUPS		Chair: Kamel Senouci, University of Geneva
13:55-14:20	How to better reach the zero-dose or under-vaccinated children in LMICs	Narendra Arora, INCLEN, India
14:20-14:40	Discussion	
14:40-15:05	Life-course vaccines: how to better reach individuals from childhood to elderly?	Ann Lindstrand, WHO, Switzerland
15:05-15:25	Discussion	
15:25-15:55	Break	
15:55-16:20	The determinants of vaccine acceptance	Eve Dube, Université de Laval
16:20-16:40	Discussion	
16:40-17:05	Interactive session 3 How to address vaccine hesitancy at individual and community levels?	Steve Lewandowsky, Bristol University Eve Dube, Université de Laval Naveen Thacker, International Pediatric Association Alejandro Cravioto, National Autonomous University of Mexico
17:05-17:25	Discussion	
17:25-17:35	Time for students to reflect personally on the learnings of the afternoon	
17:45	Departure to hotels (check bus schedule)	
18:45	Departure from Les Pensières to Les Cassines for the special reception	

FRIDAY 17 MAY 2024

SESSION 11: FACING THE MEDIA: WHAT THE VACCINOLOGIST SHOULD KNOW IN THE CONTEXT OF VACCINE HESITANCY AND ANTI-IMMUNIZATION LOBBY

Chair: **Kamel Senouci**, University of Geneva

08:30-10:30

Interactive session 4

Introduction to media dynamics: How to best deliver vaccinology-related messages to different interest groups

Deborah Hall, Broadcaster and Media Affairs Consultant, London, UK

10:30-10:50

Break

10:50-13:00

Introduction to media dynamics: How to best deliver vaccinology-related messages to different interest groups (continued)

13:00-14:00

Lunch

SESSION 12: CLOSING

Chair: **Kamel Senouci**, University of Geneva

14:00-14:30

Time for participants to complete the final evaluation (including commitment to change)

14:30-15:00

Diploma ceremony, awarding of CME credits and closure of the course

Kamel Senouci, Director, ADVAC, University of Geneva

WEDNESDAY 8 MAY 2024: SPECIAL LECTURE FROM INDUSTRY		
SESSION 3 – VACCINE TECHNOLOGY, MANUFACTURING AND APPROVAL		
16:30-18:00	<p>Interactive Session 1 From ideas to implementation - the realities of funding for vaccine research and development in the private sector</p> <p>Two 45-minutes sessions (2 groups switching) Group A: Veronica Gambillara Group B: Luis Jodar</p>	<p>Veronica Gambillara, Pureos Bioventures, Switzerland, Luis Jodar, Pfizer Inc., USA</p>